Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haider Mahdi

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Science Advances|November 12, 2021
Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibitionSandra Cascio, Chelsea Chandler, Linan Zhang, et al.
Science Advances|June 1, 2022
Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitorsXiangxue Wang, Cristian Barrera, Kaustav Bera, et al.
JCO Precision Oncology|February 9, 2022
Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center ExperienceMeena Sadaps, Pauline Funchain, Haider Mahdi, et al.
JCO Precision Oncology|September 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Haider Mahdi, Navid Hafez, Deborah Doroshow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 ImmunityBrian Orr, Haider Mahdi, Yusi Fang, et al.
Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.
Gynecologic Oncology Reports|October 17, 2022
Clinical factors associated with failed sentinel lymph node mapping in endometrial cancerAlison A Garrett, Alyssa Wield, Brigid Mumford, et al.
Brachytherapy|May 2, 2025
Twice daily template-based interstitial brachytherapy for gynecologic cancers: What is the optimal dose?Ria Mulherkar, David Grimm, Paniti Sukumvanich, et al.
Journal of Radiosurgery and SBRT|April 26, 2021
Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experienceTimothy D Smile, Chandana A Reddy, George Qiao-Guan, et al.
JCI Insight|August 16, 2022
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancerLan G Coffman, Taylor J Orellana, Tianshi Liu, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Science Advances|November 12, 2021
Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibitionSandra Cascio, Chelsea Chandler, Linan Zhang, et al.
Science Advances|June 1, 2022
Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitorsXiangxue Wang, Cristian Barrera, Kaustav Bera, et al.
JCO Precision Oncology|February 9, 2022
Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center ExperienceMeena Sadaps, Pauline Funchain, Haider Mahdi, et al.
JCO Precision Oncology|September 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Haider Mahdi, Navid Hafez, Deborah Doroshow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 ImmunityBrian Orr, Haider Mahdi, Yusi Fang, et al.
Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.
Gynecologic Oncology Reports|October 17, 2022
Clinical factors associated with failed sentinel lymph node mapping in endometrial cancerAlison A Garrett, Alyssa Wield, Brigid Mumford, et al.
Brachytherapy|May 2, 2025
Twice daily template-based interstitial brachytherapy for gynecologic cancers: What is the optimal dose?Ria Mulherkar, David Grimm, Paniti Sukumvanich, et al.
Journal of Radiosurgery and SBRT|April 26, 2021
Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experienceTimothy D Smile, Chandana A Reddy, George Qiao-Guan, et al.
JCI Insight|August 16, 2022
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancerLan G Coffman, Taylor J Orellana, Tianshi Liu, et al.
Pageof 9